Search PubMedSearch

Biomedical subjects

F C Himmler

Publications and source records attributed to F C Himmler.

12 recordsLinked to original sources

Physiological pacing: present status and future developments.

With the increasing tendency to implant pacemakers not only for life-threatening bradycardias but also for improving cardiodynamics in patients with bradycardia, it soon became apparent that classical VVI pacing is not truly able to optimize circulatory performance. Experience has shown that with ventricular pacing augmentation of cardiac output takes place only initially but is not maintained on a long-term basis, exercise capacity remains markedly reduced, there is only an unsatisfactory influence on the degree and course of heart failure and, in an occasional patient, cardiac function may even deteriorate as compared to the situation prior to pacing. Because the disappointing hemodynamic effect of fixed rate ventricular stimulation was at least partly due to the "unphysiological" mode of pacing provided by those systems which fail to restore AV synchrony and to increase heart rate with changing metabolic requirements, so called physiological pacemakers were developed. These pacing systems either maintain AV-synchrony and/or reestablish some way to adapt the pacing rate (Table I). This study delineates the hemodynamics of the paced heart with special reference to the role of AV relationship and rate control; it describes the clinical experience with physiological pacing and provides some ideas leading to present and future developments for rate adaptive pacing systems.

Atrial Fibrillation

[Use of beta-adrenergic blocking agents in acute myocardial infarction (author's transl)].

Beta-adrenergic blocking agents exert a number of pharmacologic effects which may potentially be beneficial and warrant their use in acute myocardial infarction: by decreasing heart rate, myocardial contractility and systolic blood pressure, reducing catecholamine-induced lipolysis and antagonizing the oxygen-wasting effects of catecholamines on the myocardium, myocardial oxygen balance may be improved thus reducing ischemia. Theoretically this may lead to a limitation of infarct size by protecting underperfused myocardium from ultimate necrosis. Definite proof for such a positive effect in man, however, is not yet available. In animals a number of experimental findings either indirectly of directly demonstrate the potential protective effect of beta-blockers on ischemic myocardium. Early treatment is able to significantly prolong myocardial survival time and limit the area of myocardial damage to about 50% as compared with untreated controls. Experience with treatment of myocardial infarction in man has shown that beta-blocking agents are well tolerated in patients presenting in hemodynamically stable condition (Killip groups I and II). By reducing heart rate as well as pressure and volume work of the heart and reducing serum-free-fatty-acid concentration, myocardial oxygen demand is greatly diminished. A reduction of myocardial O2-consumption and improvement in oxygen balance has been demonstrated in man. Total enzyme appearance of creatine-phosphokinase is significantly lower in patients treated with beta-blocking drugs early in the course of of myocardial infarction (within four hours following onset of acute symptoms) as compared with untreated controls. Furthermore the number of ventricular ectopic beats and the severity of chest pain are reduced. In some studies there was a significant reduction in mortality for selected groups of patients with myocardial infarction treated with beta-blocking agents. In conclusion, beta-adrenoceptor blocking agents appear to represent a promising therapeutic principle for protecting ischemic myocardium in acute infarction. Additional investigations are urgently necessary to clarify the question of which patients may profit from such management. Pending the results of such studies, a general recommendation for the treatment of myocardial infarction with beta-blockade can not yet be given.

Acute Disease

[Removal of infected entrapped pacemaker electrodes by continuous traction (author's transl)].

To remove an infected pacemaker system in order to control the infection is often difficult when there is extensive connective-tissue fixation of the electrode. Forced manual extraction may lead to severe complications. For this reason, operative removal, in certain circumstances involving cardiotomy under extracorporeal circulation, has been practised. An alternative is continuous traction in which the probe is attached peripherally and by continuous traction removed from its cardiac attachment. Nine patients have been treated successfully by this method. In eight the electrode was removed within 1-10 days without significant complications. In one instance the electrode-catheter tore within the superior vena cava after 18 days of continuous traction; the remaining catheter, about 12 cm long, was removed with a sling catheter.

Aged

[Orally active vasodilators in the management of chronic treatment-resistant cardiac failure (author's transl)].

The acute haemodynamic effects of 40 mg isosorbide dinitrate (10 subjects), 4 mg prazosin (20 subjects) and 50 mg dihydralazine (8 subjects) were compared in 24 patients with the clinical picture of chronic therapy-resistant cardiac failure (NY Heart Association stages III-IV). There was a fall in left-ventricular filling pressure of about 15% and right-atrial mean pressure of 21 and 24%, respectively, with isosorbide dinitrate and prazosin, while there was no change with dihydralazine. Cardiac output rose by 23% with dihydralazine and 20% with prazosin, but remained unchanged with isosorbide dinitrate. These data indicate that a reduction in pulmonary and systemic-venous congestion due to chronic decompensated cardiac failure can be achieved with isosorbide dinitrate and prazosin, while cardiac output can be improved only with prazosin and dihydralazine.

Adult

[Treatment of decompensated valvular disease with nitroglycerin (author's transl)].

The effects of parenteral nitroglycerin after acute and continuous infusion were investigated in 12 patients with mitral and (or) aortic valvular disease (stage IV of the New York Heart Association) and severe therapy-resistant pulmonary congestion. Intravenous injection of 1 mg led to immediate and marked decrease of right atrial mean pressure, and pulmonary artery and pulmonary capillary mean pressures, whereas mean arterial blood pressure, stroke volume index, cardiac frequency, and cardiac index remained unchanged. With a dosage of 3-10 mg/h the pressure lowering of the right circulation could be sustained. Pressure lowering of the right circulation abolished pulmonary congestion and led to marked reduction of shortness of breath. The principle of venous pooling can thus not only be used successfully in cases of increased pulmonary capillary pressure due to primary myocardial insufficiency, but also in cases with pulmonary congestion due to decompensated valvular disease.

Adult

[External mechanical cardiac stimulation. Methods and possible application (author's transl)].

External mechanical cardiac stimulation represents a noninvasive method for myocardial stimulation which has significant advantages of external electric stimulation. This paper describes a new method using pressure- and shockwaves for transthoracic cardiac stimulation. On the basis of animal experiments the potential value of external mechanical stimulation for emergency medicine and various other therapeutic and diagnostic procedures are discussed.

Animals

[Pacemaker failure due to electromagnetic interference (author's transl)].

Pacemakers may be influenced by a variety of external methods such as a magnet to test the stimulation threshold or a special programmer to change the pacers output or rate. This designed influence must not be confused with electromagnetic interference on pacemakers. The paper differenciates between functional and faulty behavior of pacemakers. A case report shows the influence of EMI by electrical devices. It is recommended to undertake field tests if EMI is likely to occur under special occupational conditions.

Disability Evaluation